The global T-Cell lymphoma market is expected to register a good CAGR during the forecast period of 2018–2023. Angio-immunoblastic T-Cell Lymphoma (AILT), also called Immunoblastic Lymphadenopathy, is a developed T-cell lymphoma of blood distinguished with the help of polymorphous lymph node penetrate causing a significant increase in the follicular dendritic cells (FDCs) and high endothelial venules (HEV) with systemic involvement. Clinically this disorder is considered as generalized lymphadenopathy and high fever.
According to the National Council on Radiation Protection and Measurements (NCRP), the average annual radiation dose per person in the United States is 620 millirem (6.2 millisieverts), which is very high as compared to the United Kingdom with 1.8 millisieverts. Continuous exposure to radiation over a long period of time results in skin cancers and tumors. According to the American Cancer Society (ACS), in 2016 estimated males having lymphoma were 6% (1,460) and estimated females having lymphoma were 4% (1,170), and the estimated deaths of males were 4% (320) and females were 3% (290).
Therefore, the high average annual radiation dose per person will increase the number of T-cell lymphoma incidences every year, which along with increasing estimated deaths per year is expected to contribute to the growth of global T-cell lymphoma market.
The other factors, such as increase in number of T-Cell lymphoma specific therapies and the risk of lymphoma due to autoimmune disorders are driving the T-cell lymphoma market.
The increase in cancer drug prices in the last 15 years has been a problem for the global population. Patients who have developed cancer cannot afford treatment, due to the high cost of treatment. According to a 2013 study by The Oncologist, a journal devoted to medical and practice issues for surgical, radiation, and medical oncologists, about 20% cancer patients filled only part of a prescription or took less than the prescribed amount. About 1.6 million Americans were diagnosed with cancer in 2017, and this suggests that only 168,000 to 405,000 patients will have their own prescription use. According to Kaiser Family Foundation, Revlimid drug, which is used for the treatment of Lymphoma cancer, can cost USD 11,538 annually, which is an out-of-pocket cost and is not included in health insurance, like Medicare. Thus, with these health insurance plans and higher cost of treatment, it is very difficult for everyone to afford cancer therapies or drugs, which is restraining the T-cell lymphoma market. The other factor, such as the adverse side effects of therapies is also hindering the growth of the market.
The United States T-cell lymphoma market held the largest market share in 2017 in the North America region due to the presence of high-quality healthcare system and modern medical technology in the country. Additionally, the growing awareness among the public about cancer is likely to contribute towards the growth of the T-cell lymphoma market.
The major players include Bristol-Myers Squibb, Celgene Corporation, Johnson & Johnson, Novartis, Roche Holding, Genmab A/S, Shionogi & Company Limited, Biocryst Pharmaceuticals, Inc., and Spectrum Pharmaceuticals, among others.
Looking to Customize Report?